SVRA

Savara Inc

Add to Watchlist

Advanced Chart

2.649

-0.011(-0.414%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.660

Open

2.630

VWAP

Vol

80.46K

Mkt Cap

459.75M

Low

2.600

Amount

EV/EBITDA(TTM)

Total Shares

138.19M

316.77M

EV/OCF(TTM)

P/S(TTM)

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.120

-7.69%

-0.122

+10.91%

-0.120

-0%

Estimates Revision

The market is revising No Change the revenue expectations for Savara Inc. (SVRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -18.74%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.54%

In Past 3 Month

Stock Price

Go Down

-18.74%

In Past 3 Month

7 Analyst Rating

164.25% Upside

Wall Street analysts forecast SVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SVRA is 7.00 USD with a low forecast of 2.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

164.25% Upside

Current: 2.649

Low

2.00

Averages

7.00

High

16.00

164.25% Upside

Current: 2.649

Low

2.00

Averages

7.00

High

16.00

Oppenheimer

Outperform

Underperform

downgrade

$15 -> $5

2025-06-02

Reason

Oppenheimer

Price Target

$15 -> $5

2025-06-02

downgrade

Outperform

Underperform

Reason

Oppenheimer assumed coverage of Savara with an Outperform rating with a price target of $5, down from $15, following quarterly results. Management announced it received a Refusal to File for its BLA for Molbreevi, with the FDA requesting additional CMC data. The firm says that while unexpected, it's encouraging that the RTF was not related to safety or efficacy, and no additional efficacy trials were requested/recommended. Based on the strength of the Phase 3 IMPALA trial, and considering the lack of approved drug therapies and the challenges of whole lung lavage, Oppenheimer still believes Molbreevi is well-positioned for commercial success. New ATS data further supports its clinical potential. Savara also remains on track to submit Molbreevi MAA in Europe and U.K. by year-end 2025, the firm adds.

H.C. Wainwright

Buy -> Neutral

downgrade

$6 -> $2

2025-05-29

Reason

H.C. Wainwright

Price Target

$6 -> $2

2025-05-29

downgrade

Buy -> Neutral

Reason

Wells Fargo

Overweight

maintain

$8 -> $7

2025-05-28

Reason

Wells Fargo

Price Target

$8 -> $7

2025-05-28

maintain

Overweight

Reason

Wells Fargo lowered the firm's price target on Savara to $7 from $8 and keeps an Overweight rating on the shares after the company said it received an RTF letter for Molbreevi's BLA submission, and that the FDA requested additional data related to CMC. The firm notes RTF was not related to safety concerns or the need for additional efficacy data, and management is confident in a path to approval, especially with optionality from two CDMOs. While unexpected, Wells thinks the fundamental impact of the delay is limited.

Guggenheim

Vamil Divan

Buy

downgrade

$9 -> $8

2025-05-28

Reason

Guggenheim

Vamil Divan

Price Target

$9 -> $8

2025-05-28

downgrade

Buy

Reason

Evercore ISI

analyst

In Line

downgrade

$3 -> $2

2025-05-28

Reason

Evercore ISI

analyst

Price Target

$3 -> $2

2025-05-28

downgrade

In Line

Reason

Citizens JMP

Outperform

downgrade

$10 -> $9

2025-05-14

Reason

Citizens JMP

Price Target

$10 -> $9

2025-05-14

downgrade

Outperform

Reason

Citizens JMP lowered the firm's price target on Savara to $9 from $10 and keeps an Outperform rating on the shares. Priority review for Molbreevi could provide a boost to shares in the near-term as management is laser-focused on a potential launch in early 2026, the analyst tells investors in a research note. The firm expects the FDA to accept the submission this month with a PDUFA date possibly by year-end.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Savara Inc (SVRA.O) is -5.09, compared to its 5-year average forward P/E of -6.50. For a more detailed relative valuation and DCF analysis to assess Savara Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.50

Current PE

-5.09

Overvalued PE

-3.48

Undervalued PE

-9.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.38

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.12

Undervalued EV/EBITDA

-4.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.12

Current PS

0.00

Overvalued PS

4.22

Undervalued PS

-3.99